Case-control study associates cellular senescence-related gene variants with recurrent pregnancy loss

A genetic association study reported that specific variants and genotype combinations in the core cellular senescence regulators CDKN1A and CDKN2A are associated with susceptibility to recurrent pregnancy loss.

A study published in Molecular Biology Reports evaluated the role of cellular senescence-related genes in recurrent pregnancy loss (RPL), a condition affecting 1–2% of couples.

The researchers conducted a case-control analysis involving 107 women undergoing investigation for RPL and 118 fertile controls to assess variants in CDKN1A, CDKN2A, AKT1, EP300, TNF, and IFNG.

While secondary differential gene expression analysis of endometrial and placental public datasets did not show significant differences, genetic variants did correlate with the condition.

The CDKN1A rs2395655 allele A was more frequent in patients with RPL than in controls (p = 0.001).

Analysis of genotype combinations revealed that the combination of CDKN1A rs2395655 AG and CDKN2A rs11515 GG was associated with increased susceptibility to RPL (adjusted OR = 2.150, 95% CI: 1.066–4.438), with statistical power reported at 72.7%.

Conversely, the CDKN1A rs2395655 AG and CDKN2A rs11515 CG genotype combination was associated with decreased susceptibility to the condition (adjusted OR = 0.246, 95% CI: 0.069–0.763), with statistical power at 72.4%.

Up to 50% of recurrent pregnancy loss cases are currently classified as idiopathic. Uncovering genetic factors in cellular senescence pathways offers a potential mechanism to explain a portion of these unresolved cases.

CDKN1A (encoding p21) and CDKN2A (encoding p16) are central regulators of cell cycle arrest and cellular senescence. Under physiological conditions, senescent cells and their associated secretory phenotype (SASP) facilitate tissue remodeling, vascular development, and uterine receptivity during pregnancy.

The study suggests that genetically determined dysfunction or altered expression patterns in these core senescence mediators could disrupt maternal-fetal coordination, leading to pregnancy loss.

The findings expand the physiological and diagnostic scope of cellular senescence beyond typical age-related degenerative indications, such as osteoarthritis or macular degeneration.

Developing therapeutics or predictive biomarkers for reproductive health represents an unaddressed pipeline expansion area for the longevity biotechnology sector.

However, because transient cellular senescence is essential for physiological embryonic and placental development, therapeutic interventions targeting senescent cells in this space would face high regulatory and safety bars, requiring exceptional tissue-specific or localized delivery to avoid developmental toxicity.

Independent cohort studies to validate these preliminary genetic associations in broader and more ethnically diverse populations.

Functional biological studies to clarify how the rs2395655 and rs11515 variants alter p21 and p16 protein expression or signaling kinetics within the endometrium and placenta.